Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 1/20 | 0.44 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | VCP | P55072 | 1/20 | 0.39 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.38 |
| ▸ | WNT1 | P04628 | 4/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23901680 | 0.91 | POLB (0.41) | CRHR1CRHR2CHRM4TP53DYRK1A | |
| SCHEMBL23901595 | 0.91 | CRHR1 (0.38) | CRHR1CRHR2CHRM4TP53VCP | |
| SCHEMBL19449370 | 0.86 | CRHR1 (0.41) | CRHR1CRHR2VCPDYRK1AWNT1 | |
| SCHEMBL19449422 | 0.85 | DYRK1A (0.49) | CRHR1CRHR2DYRK1AWNT1 | |
| SCHEMBL19438272 | 0.83 | TYRO3 (0.41) | CRHR1CRHR2TYRO3DYRK1AWNT1 | |
| SCHEMBL19449609 | 0.82 | DYRK1A (0.47) | DYRK1AADORA2ALMNA | |
| SCHEMBL19437874 | 0.82 | CRHR1 (0.45) | CRHR1CRHR2DYRK1AWNT1 | |
| SCHEMBL19437872 | 0.82 | CRHR1 (0.45) | CRHR1CRHR2DYRK1AWNT1 | |
| SCHEMBL23901676 | 0.81 | TRPV1 (0.43) | TP53LMNA | |
| SCHEMBL24080656 | 0.80 | ALDH1A1 (0.55) | CRHR1CRHR2CHRM4TP53LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210309661-A1 | IMIDAZO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2021-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210309661-A1 | IMIDAZO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GBA1, GAA, GBA2 | CRHR1 3609/4885CRHR2 3728/4885CHRM4 1486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.